Karyopharm Therapeutics Inc. (KPTI) analyst actions
Rating and price-target actions on KPTI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the KPTI overview →
1 measured KPTI analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 | Press release | -3.85% | -5.15% |
Keep exploring
More KPTI: earnings → · SEC filings → · KPTI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.